sr141716 has been researched along with Polycystic Ovary Syndrome in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Elshewehy, AM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Atkin, SL; Coady, AM; Javed, Z; Kilpatrick, ES; Sathyapalan, T | 1 |
| Kapoor, S | 1 |
| Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T | 2 |
| Atkin, SL; Cho, L; Coady, AM; Kilpatrick, ES; Le Roux, CW; Sathyapalan, T | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
1 review(s) available for sr141716 and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
6 trial(s) available for sr141716 and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss | 2017 |
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2016 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammation; Interleukin-8; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Vascular Endothelial Growth Factor A; Weight Loss | 2017 |
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Female; Humans; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Testosterone; Weight Loss | 2009 |
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
Topics: Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2010 |
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Testosterone; Weight Loss | 2008 |
1 other study(ies) available for sr141716 and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
Topics: Cannabinoid Receptor Antagonists; Depression; Female; Humans; Metabolic Diseases; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2009 |